Evaluating markers to predict radioresistance in head and neck cancer
Do Markers of Systemic Inflammatory Response and Tumor Metabolism Indicate Radioresistance in Head and Neck Cancer?
This study is testing if certain blood markers and imaging results can help predict how well patients with advanced head and neck cancer will respond to radiation treatment before they start therapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Luzerner Kantonsspital Academic / other |
| Locations | 1 site (Lucerne) |
| Trial ID | NCT05217212 on ClinicalTrials.gov |
What this trial studies
This observational study aims to prospectively assess whether systemic inflammatory response markers and FDG-PET/CT metabolic parameters can predict radioresistance and survival in patients with advanced head and neck squamous cell carcinoma before they undergo primary radiochemotherapy. It will analyze various blood markers and imaging results to determine their prognostic value. The study focuses on patients with a confirmed diagnosis who are preparing for curative treatment.
Who should consider this trial
Good fit: Ideal candidates include patients with a histopathologic diagnosis of squamous cell carcinoma of the head and neck who are about to receive primary radiochemotherapy.
Not a fit: Patients with other types of head and neck tumors or those who have undergone primary surgical treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify patients who are likely to benefit from radiochemotherapy, potentially improving treatment outcomes.
How similar studies have performed: While there have been studies investigating similar markers in cancer treatment, this specific approach focusing on systemic inflammatory response and metabolic parameters in head and neck cancer is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * histopathologic diagnosis of squamous cell carcinoma of the head and neck * primary radio(chemo)therapy with curative intent * available pretherapeutic FDG-PET/CT imaging * available pretherapeutic differential blood analysis Exclusion Criteria: * other tumor entities of the head and neck including cutaneous squamous cell carcinoma * primary surgical treatment * ongoing infections or other inflammatory diseases at the time of diagnosis * patients not completing a course of irradiation with at least 66 Gray locally
Where this trial is running
Lucerne
- Department of Otorhinolaryngology - Head and Neck Surgery, Cantonal Hospital Lucerne — Lucerne, Switzerland (Recruiting)
Study contacts
- Study coordinator: Jonas Werner, MD
- Email: jonas.werner@luks.ch
- Phone: 0041442059455
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.